Published on 2 May 2024 on GuruFocus.com via Yahoo Finance
Puma Biotechnology Inc (PBYI) Reports Q1 Financial Results, Misses Analyst Revenue and EPS Forecasts
Revenue: Reported at $43.8 million, exceeding estimates of $41.05 million.Net Loss: Posted a net loss of $4.8 million, significantly better than the estimated net loss of $10.20 million.Earnings Per Share (EPS): Recorded at -$0.10, surpassing the estimated EPS of -$0.22.Operating Cash Flow: Net cash provided by operating activities reached $11.3 million, compared to $2.6 million in the previous year.Cost of Sales: Decreased to $10.7 million from $13.2 million year-over-year, reflecting lower royalty expenses due to decreased sales.Research and Development Expenses: Increased to $13.6 million, primarily due to higher clinical trial expenses.Liquidity: Cash, cash equivalents, and marketable securities stood at $107.2 million as of March 31, 2024.
Warning! GuruFocus has detected 4 Warning Signs with PBYI.